Thiamphenicol Enteric-coated Tablets

This product is a congener of chloramphenicol. Its antibacterial spectrum and antibacterial effect are similar to those of chloramphenicol. It has a broad-spectrum antimicrobial effect, including aerobic Gram-negative and Gram-positive bacteria, anaerobic bacteria, Rickettsia, spirochetes and Chlamydia. Thiamphenicol has a bactericidal effect on the following bacteria: Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis. It only has an inhibitory effect on the following bacteria: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans, Group B hemolytic Streptococcus, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Salmonella typhi, Salmonella paratyphi, Shigella, Bacteroides fragilis and other anaerobic bacteria. The following bacteria are usually resistant to chloramphenicol: Pseudomonas aeruginosa, Acinetobacter, Enterobacter, Serratia marcescens, indole-positive Proteus, methicillin-resistant Staphylococcus and Enterococcus. This product is an antibacterial agent. It reversibly binds to the 50S subunit of the bacterial ribosome, which blocks the growth of the peptide chain (probably due to the inhibition of the action of the transpeptidase), thus inhibiting the formation of the peptide chain and preventing protein synthesis. It is completely cross-resistant with chloramphenicol. Since thiamphenicol does not bind to glucuronic acid in the liver, it has a high antibacterial activity in vivo. This product also has a strong immunosuppressive effect, which is about 6 times stronger than chloramphenicol.

The main component of this product is thiamphenicol, and its chemical name is [R-(R*,R*)]N-[1-(hydroxymethyl)-2-hydroxy-2-[4-(methylsulfonyl)phenyl]ethyl]2,2,-dichloroacetamide. Its structural formula is: Molecular formula: C12H15Cl2NO5S Molecular weight: 356.23

This product is enteric-coated tablets, which appear white after removing the coating.

Used for respiratory tract, urinary tract, intestinal and other infections caused by sensitive bacteria such as Haemophilus influenzae, Escherichia coli, Salmonella, etc.

Oral administration: adults 1.5-3g per day, divided into 3-4 times; children 25-50mg/Kg per day according to body weight, divided into 4 times.

1. Abdominal pain, diarrhea, nausea, vomiting and other digestive tract reactions may occur, with an incidence rate of less than 10%. 2. Allergic reactions such as rashes are occasionally seen. 3. Gray baby syndrome has not been found in premature infants and newborns. Only individual cases have been reported of transient skin and facial pallor. 4. This product can also cause toxic reactions in the hematopoietic system, mainly manifested as reversible inhibition of erythropoiesis, leukopenia and thrombocytopenia; aplastic anemia is rare.

It is contraindicated for those who are allergic to this product.

Precautions for children: Avoid using in newborns. Precautions for pregnancy and lactation: Pregnant women, especially those in the late stages of pregnancy, should avoid using the drug as much as possible. Lactating women should stop breastfeeding when using the drug. Precautions for the elderly: Not clear yet.

1. Antiepileptic drugs (hydantoins). Since this product can inhibit the activity of liver cell microsomal enzymes, resulting in reduced metabolism of such drugs, or this product replaces the serum protein binding site of such drugs, it can enhance the effect of the drugs or increase toxicity. Therefore, when used with this product or after it, the dosage of such drugs must be adjusted. 2. When this product is used with hypoglycemic drugs (such as tolbutamide), its hypoglycemic effect can be enhanced due to the replacement of protein binding sites, so the dosage of such drugs needs to be adjusted. The non-ionic binding characteristics of glipizide and glyburide are less affected than other oral hypoglycemic drugs, but caution should still be exercised when the two are used together. 3. Long-term oral estrogen-containing contraceptives can reduce the reliability of contraception and increase menstrual bleeding when taking this product at the same time. 4. Since this product can have the effect of vitamin B6 antagonists or increase the renal excretion of the latter, it can cause anemia or peripheral neuritis. Therefore, when this product is used with vitamin B6, the dose of the latter should be appropriately increased. 5. This product can antagonize the hematopoietic effect of vitamin B12, so the two should not be used together. 6. When used in combination with certain bone marrow suppressive drugs, it can enhance the bone marrow suppressive effect. Anti-tumor drugs, colchicine, hydroxyphenylbutazone, phenylbutazone and penicillamine are all such drugs. When radiotherapy is performed at the same time, it can also enhance the bone marrow suppressive effect, and the dose of bone marrow suppressants or radiotherapy must be adjusted. 7. If this product is used before or during surgery, due to its inhibitory effect on liver enzymes, it can reduce the clearance of the induced anesthetic alfentanil and prolong its duration of action. 8. When liver enzyme inducers such as phenobarbital and rifampicin are used together with this product, it can enhance the metabolism of this product and cause a decrease in the blood concentration of sulfamic acid. 9. Lincomycins can replace or prevent the binding of this product to the 50S subunit of the bacterial ribosome. The two can have antagonistic effects when used together, so they should not be used together.

Keep away from light, sealed and stored in a dry place.

0.25g

24 months

Fuzhou FU Yao Pharmaceutical Co., Ltd.

• Founded in:

  2001-06-07

• Address:

  No. 279, Zhongxia, Gushan Town, Jin'an District, Fuzhou City

• Tax NO.:

  91350100727934373D

• Registered Funds:

  30 million yuan

• Website:

  Log in to view

• Email:

  Log in to view